MEFV and familial Mediterranean fever: Given that colchicine treatments are known to induce the release of GEF-H1 from microtubules [19] and GEF-H1 is the specific activator for RhoA [16,17], it would be critical to examine whether GEF-H1 regulates the pyrin inflammasome activation that plays a critical role in pyrin-mediated autoinflammatory disorders such as familial Mediterranean fever (FMF) and hyperimmunoglobulinemia D syndrome (HIDS) [33,36].